BofA raised the firm’s price target on Argenx (ARGX) to $942 from $887 and keeps a Buy rating on the shares. The firm, which models Q3 Vyvgart revenues of $1.07B, expects continued growth in generalized myasthenia gravis, driven by geographic expansion, as well as label expansion into seronegative patients, the analyst tells investors in a preview. The firm remains “bullish” on Vyvgart’s commercial opportunity, with multiple avenues for growth, the analyst added.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx’s Vyvgart: Strong Performance and Growth Potential Drive Buy Rating
- Argenx SE Showcases Immunology Innovations at 2025 AANEM Meeting
- Argenx price target raised to $880 from $800 at Wedbush
- Argenx SE Calls Extraordinary Shareholder Meeting for November 2025
- Argenx price target raised to $1,040 from $766 at Morgan Stanley